Lalmohamed
When a new medicine is granted marketing authorization, its clinical safety has been assessed on data from strictly controlled randomized trials. However, when the drug is approved, it is used by patients in settings that are quite different from the rarified clinical trial setting (e.g. older patients, children, polypharmacy, multi-comorbidity and pregnancy). By using ‘real world data’ from thousands of individuals after drug approval, pharmacoepidemiology may reveal novel unintended drug effects, both detrimental or beneficial.
My team focuses on immuno-pharmacoepidemiology and studies (1) real world safety and efficacy of licensed immune modulating drugs and (2) drug repurposing (i.e., identifying novel therapeutic uses for licensed drugs) within immune mediated diseases.
Specialisms:
- Clinical Pharmacoepidemiology
- Cancer Immunotherapy
- Hematopoietic Cell Transplantation
- Auto-Immune Diseases
Theses
